Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs.
The purpose of the study was to assess the pharmacokinetics of liposome-encapsulated (DPPC-C) hydromorphone administered intravenously (IV) or subcutaneously (SC) to dogs. A total of eight healthy Beagles aged 12.13 +/- 1.2 months and weighing 11.72 +/- 1.10 kg were used. Dogs randomly received liposome encapsulated hydromorphone, 0.5 mg/kg IV (n = 6), 1.0 mg/kg (n = 6), 2.0 mg/kg (n = 6), or 3.0 mg/kg (n = 7) SC with a 14-28 day washout between trials. Blood was sampled at serial intervals after drug administration. Serum hydromorphone concentrations were measured using liquid chromatography with mass spectrometry. Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg). The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively. The maximum serum concentration normalized for dose (C(MAX)/D) ranged between 19.41-24.96 ng/mL occurring at 0.18-0.27 h. Serum hydromorphone concentrations fluctuated around 4.0 ng/mL from 6-72 h after 2.0 mg/kg and mean concentrations remained above 4 ng/mL for 96 h after 3.0 mg/kg DPPC-C hydromorphone. Liposome-encapsulated hydromorphone (DPPC-C) administered SC to healthy dogs provided a sustained duration of serum hydromorphone concentrations.
Smith
L J
LJ
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA. smithl@svm.vetmed.wisc.edu
KuKanich
B
B
Hogan
B K
BK
Brown
C
C
Heath
T D
TD
Krugner-Higby
L A
LA
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D019540:Area Under Curve; D002626:Chemistry, Pharmaceutical; D004285:Dogs; D006207:Half-Life; D004091:Hydromorphone / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D007279:Injections, Subcutaneous; D008081:Liposomes; D008297:Male; D008657:Metabolic Clearance Rate
D000701:Analgesics, Opioid; D008081:Liposomes; D004091:Hydromorphone